Benmelstobart: all 67 studies that test it

Page 1 of 1. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLCNot yet recruitingNCT07643350Phase 2
• Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial NephrectomyNot yet recruitingNCT07627464Phase 2
• Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingNCT07602101Phase 2
• A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07538271Phase 2
• Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingNCT07538258Phase 2
• Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
• Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07535567Phase 2/3
• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingNCT07510594Phase 2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• Anlotinib and Benmelstobart in DTCNot yet recruitingNCT07193186Phase 2
• Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
• Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06931145Phase 4
• TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd ECRecruitingNCT06914297Phase 2
• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingNCT06767800Phase 2
• Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
• Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingNCT06699498Phase 2
• Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Phase 2
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• The Efficacy and Safety of Benmelstobart for GC/EGCNot yet recruitingNCT06603974Not applicable
• Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaRecruitingNCT06528847Phase 2
• Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerNot yet recruitingNCT06475599Phase 3
• A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNot yet recruitingNCT06469879Phase 3
• Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
• Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and ChemotherapyRecruitingNCT05942508Phase 1
• A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Phase 2
• Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
• TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingNCT05718167Phase 3
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT05252078Phase 2
• PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung CancerRecruitingNCT04539977Phase 2
• Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT07881900Phase 3
• A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 ExpressionActive, not recruitingNCT06939452Phase 2
• Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Phase 2
• Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid TumorsStatus unknownNCT05645315Phase 1/2
• Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different GenotypesStatus unknownNCT05608785Phase 1/2
• A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).Status unknownNCT05346952Phase 3
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerStatus unknownNCT05145218Phase 3
• TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After ResectionStatus unknownNCT05111366Phase 2
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Phase 3
• A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaCompletedNCT04895345Phase 2
• TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT04891900Not applicable
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerStatus unknownNCT04809142Phase 3
• Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCStatus unknownNCT04665609Phase 3
• A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical CancerStatus unknownNCT04623333Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerCompletedNCT04574284Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerActive, not recruitingNCT04523272Phase 3
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Phase 3
• A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Phase 3
• A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04306926Phase 2
• A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological CancerStatus unknownNCT04236362Phase 1/2
• A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
• Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)CompletedNCT04202653Phase 2
• Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Phase 2
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced CholangiocarcinomaStatus unknownNCT03996408Phase 1/2
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant MelanomaStatus unknownNCT03991975Phase 1/2
• Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung CancerStatus unknownNCT03983928Phase 1/2
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）Status unknownNCT03910127Phase 1
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid TumorsStatus unknownNCT03897283Phase 1
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
• A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaStatus unknownNCT03800706Phase 2
• Tolerance and Pharmacokinetics of TQB2450Status unknownNCT03460457Phase 1

← Benmelstobart overview